Gene test could Fine-Tune transplant drug dosing

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients, male or female, 18 to 65 years old. * Patients receiving a first or a second isolated renal graft coming from a donor alive or deceased, * The patients in age to procreate must have a negative test of pregnancy before being included in this study and will have to agree to use effective contraceptive measurements throughout the study. -Patients able to include/understand the aims and the risks of the study, -having been fully informed and having given their writing consent to take part in this study. Patients unable to write and/or read but having fully understood the oral information given by the investigator and having given their oral consent in the presence of an independent witness. - Exclusion Criteria: * Patients who receive several grafts. * Patients requiring a treatment by azathioprin. * Pregnant woman or nursing mother * Patients receiving an incompatible graft ABO. * Patients receiving or requiring immunosuppressant drugs prohibited by the protocol. * Patients with a peak of historical antibody equal to or greater than 50% of the panel. * Patients suffering from serious gastro-intestinal disorders which interfere with their capacity to receive or to absorb an oral form and patients presenting severe diarrhoea. * Patients with symptomatic GI ulcer HIV or HTLV1 positive patients or their donors * Patients presenting or having presented in the 5 last years one or several malignant tumours, except baso or spinocellular cutaneous epithelioma successfully treated. * Patients with systemic infections requiring a treatment at the entry in the study. * Patients having a leukocyte numeration lower than 2,5.109/l or haemoglobin lower than 5g/dl. * Patients with drug-addiction whatever it is, or psychiatric disorder which, according to the point of view of the investigator, could invalidate the communication with investigator or interfere with the compliance of the patient. * Patients who take part simultaneously in another therapeutic test or who received a study treatment less than 30 days before the entry in this study. * Patients having already been included in this study. * Patients allergic or intolerant with corticoids, macrolides, Tacrolimus, mycophenolate mofetil or basiliximab